Genetic+Donguibogam
-
KAIST to support the Genetic Donguibogam Research Project for global market entry of a new natural drug produced by Green Cross Corporation HS
In the wake of the spread of the Middle East Respiratory Syndrome (MERS), sales of immune-enhancing products in Korea such as red and white ginseng have risen dramatically. Ginseng is one of Korea’s major health supplement it exports, but due to the lack of precise scientific knowledge of its mechanism, sales of ginseng account for less than 2% of the global market share.
The Genetic Donguibogam Research Project represents a group of research initiatives to study genes and environmental factors that contribute to diseases and to discover alternative treatments through Eastern medicine. The project is being led by KAIST’s Department of Bio & Brain Engineering Professor Do-Heon Lee.
Professor Lee and Chief Executive Officer Young-Hyo Yoo of Green Cross Corporation HS, a Korean pharmaceutical company, signed a memorandum of understanding (MOU), as well as a non-disclosure agreement (NDA) to develop a naturally derived drug with an enhanced ginsenoside, pharmacological compounds of ginseng, for the global market entry of BST204 on June 10, 2015.
Donguibogam is the traditional Korean source for the principles and practice of Eastern medicine, which was compiled by the royal physician Heo Jun and first published in 1613 during the Joseon Dynasty of Korea.
Cooperating with Green Cross Co., HS, KAIST researchers will use a multi-component, multi-target (MCMT)-based development platform to produce the new natural drug, BST204. This cooperation is expected to assist the entry of the drug into the European market.
Green Cross Co., HS has applied a bio-conversion technique to ginseng to develop BST204, which is a drug with enhanced active constituent of aginsenosides. The drug is the first produced by any Korean pharmaceutical company to complete the first phase of clinical trials in Germany and is about to start the second phase of trials.
Professor Do-Heon Lee, the Director of the project said, “Genetic Donguibogam Research Project seeks to create new innovative healthcare material for the future using integrated fundamental technologies such as virtual human body computer modelling and multi-omics to explain the mechanism in which natural ingredients affect the human body.” He continued, “Especially, by employing the virtual human body computer modelling, we can develop an innovative new technology that will greatly assist Korean pharmaceutical industry and make it the platform technology in entering global markets.”
Young-Hyo Yoo, the CEO of Green Cross Co., HS, said, “For a new naturally derived drug to be acknowledged in the global market, such as Europe and the US, its mechanism, as well as its effectiveness and safety, should be proven. However, it is difficult and costly to explain the mechanism in which the complex composition of a natural substance influences the body. Innovative technology is needed to solve this problem.”
Professor Do-Heon Lee (left in the picture), the Director of Genetic Donguibogam Research Project, stands abreast Young-Hyo Yoo (right in the picture), the CEO of Green Cross Co., HS.
2015.06.10 View 7731 -
Opening Ceremony of Genetic Donguibogam held
- Medicine using traditional natural substances • Food product source technology development begins
- Over 150,000,000,000 Won for 10 years of work invested to develop source technology
- Opening ceremony held on November 26th at 3 p.m. in Bio & Brain Engineering Division Building
The research to develop medicine and food source technology using traditional natural substances hasbegun.The opening ceremony of the “Genetic Donguibogam” business group, with KAIST Department of Bio & Brain Engineering Professor Do Heon Lee as the leader, was held on November 26th at 3 p.m. in Dream Hall, Bio & Brain Engineering Division Building, KAIST, Daejeon. The attendees of the opening ceremony included Yo Eop Im, Head of the Future Technology Department of the Ministry of Science, ICT and Future Planning and around 200 experts in science and technology industry, including the National Research Foundation of Korea, KAIST, the Korea Institute of Science and Technology, Seoul National University and Yonsei University.
The business group was established to re-interpret traditional natural substances proved to be effective from experience and improve quality of life by researching its applications; and to develop integrated source technology using traditional natural substances. The group is to invest over 150,000,000,000 Won for 10 years of research to secure natural substance source technology in five stages: interpretation technology, analysis technology, verification technology, bio marker technology and human body effectiveness verification technology. Especially, the focus would be on the use of virtual body computer models and Omics* to analyse the effects of traditional natural substances mixture on human body, and to find new materials for healthcare.
This research model, it is hoped, will have a new item to pioneer in the world natural substance market as well as securing a technologically competitive edge in bio industry by developing source technology that investigates the effects of traditional natural substances using cutting edge science.
KAIST Department of Bio & Brain Engineering Professor and Head Do Heon Lee of the “Genetic Donguibogam” Business Group said, “We will push forward to develop source energy by integrating IT-BT technology with a computer virtual body to build a cooperation system with medicine and functional food industries.” He continued: “This will enable not only the creation of a new industry, but also customised medicine.”
The 12 partners of the group include KAIST, Korea Institute of Science and Technology, Seoul National University and Yonsei University and 200 experts. The research participation area will be widened to foreign research institutes and associated companies.
* Terminology
Noun) Omics is an academic discipline analysing mass information on metabolism of physiological phenomena in specific cells (transcriptome, proteome and protoplast) with an integrated approach to determine vital phenomena.
2013.12.11 View 8492